• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)

    Simply Wall St·07/29/2026 11:15:17
    Listen to the news
    • In July 2026, InnoCare Pharma reported that its oral TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistically significant, clinically meaningful benefits and a consistent safety profile in a registrational Phase III trial for adults with moderate-to-severe plaque psoriasis.
    • This success further underscores InnoCare’s push into oral TYK2 therapies across multiple autoimmune skin diseases, potentially broadening its late-stage dermatology portfolio beyond oncology-led revenue streams.
    • We’ll now examine how this Phase III success for fadeucravacitinib in psoriasis could influence InnoCare Pharma’s broader investment narrative and growth priorities.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    InnoCare Pharma Investment Narrative Recap

    To own InnoCare, you need to believe its transition from an oncology-centric story toward a broader autoimmune and dermatology franchise can support the current valuation despite forecast earnings declines. The Phase III win for fadeucravacitinib in psoriasis strengthens the TYK2 narrative and may become a key nearer term catalyst, potentially easing concerns that high R&D spend and pipeline breadth might not translate into commercially relevant late stage assets.

    The recent Phase III success of soficitinib in moderate to severe atopic dermatitis is particularly relevant here, as it reinforces the TYK2 class across multiple skin diseases. Together with ICP 488 in psoriasis, this adds depth to InnoCare’s dermatology pipeline beyond orelabrutinib, which could help mitigate concentration risk if these programs move through regulatory review and into commercialization as planned.

    Yet, while these TYK2 wins are encouraging, investors should still be aware that...

    Read the full narrative on InnoCare Pharma (it's free!)

    InnoCare Pharma's narrative projects CN¥3.8 billion revenue and CN¥205.8 million earnings by 2029.

    Uncover how InnoCare Pharma's forecasts yield a HK$19.62 fair value, a 40% upside to its current price.

    Exploring Other Perspectives

    SEHK:9969 1-Year Stock Price Chart
    SEHK:9969 1-Year Stock Price Chart

    While the psoriasis data could strengthen the TYK2 story, the most pessimistic analysts still saw earnings falling to about CN¥412.4 million by 2029 and margins compressing sharply, so you should expect very different interpretations of today’s news and be open to comparing several viewpoints before deciding what it means for you.

    Explore another fair value estimate on InnoCare Pharma - why the stock might be worth as much as 40% more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.